PHA Canada is proud to announce our latest submission to the Patented Medicines Pricing Review Board (PMPRB) this September. As the voice of the PH community, we are actively working to ensure that any changes to Canada's drug pricing regulations do not hinder patients’ ability to access new, life-saving therapies.
The regulatory landscape is complex, but our goal is simple: to protect the interests of PH patients by advocating for fair and timely access to the latest treatments. By continuing to engage with policymakers, we strive to make sure that these changes support the PH community’s ability to receive the care they need.
Comments